Compare Piramal Healthcare with Sun Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PIRAMAL ENTERPRISES vs SUN PHARMA - Comparison Results

PIRAMAL ENTERPRISES     Change

Piramal Enterprises has a presence in custom manufacturing, critical care OTC and financial services. To give a boost to its custom manufacturing operations, the company had acquired Avecia Pharmaceuticals, UK in 2005 and Pfizer's Morpeth facility in... More

SUN PHARMA 
   Change

Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PIRAMAL ENTERPRISES SUN PHARMA PIRAMAL ENTERPRISES/
SUN PHARMA
 
P/E (TTM) x -34.0 118.8 - View Chart
P/BV x 1.1 3.0 38.6% View Chart
Dividend Yield % 2.0 0.5 375.6%  

Financials

 PIRAMAL ENTERPRISES   SUN PHARMA
EQUITY SHARE DATA
    PIRAMAL ENTERPRISES
Mar-19
SUN PHARMA
Mar-19
PIRAMAL ENTERPRISES/
SUN PHARMA
5-Yr Chart
Click to enlarge
High Rs3,303679 486.5%   
Low Rs1,797375 478.6%   
Sales per share (Unadj.) Rs716.5121.1 591.4%  
Earnings per share (Unadj.) Rs79.713.4 595.9%  
Cash flow per share (Unadj.) Rs107.920.7 521.7%  
Dividends per share (Unadj.) Rs28.002.75 1,018.2%  
Dividend yield (eoy) %1.10.5 210.5%  
Book value per share (Unadj.) Rs1,477.5172.6 856.1%  
Shares outstanding (eoy) m184.452,399.26 7.7%   
Bonus/Rights/Conversions IS--  
Price / Sales ratio x3.64.4 81.8%   
Avg P/E ratio x32.039.4 81.2%  
P/CF ratio (eoy) x23.625.5 92.7%  
Price / Book Value ratio x1.73.1 56.5%  
Dividend payout %35.120.6 170.9%   
Avg Mkt Cap Rs m470,2921,264,650 37.2%   
No. of employees `0007.817.5 44.7%   
Total wages/salary Rs m22,50459,671 37.7%   
Avg. sales/employee Rs Th16,899.416,608.1 101.8%   
Avg. wages/employee Rs Th2,877.73,409.6 84.4%   
Avg. net profit/employee Rs Th1,879.91,833.8 102.5%   
INCOME DATA
Net Sales Rs m132,153290,659 45.5%  
Other income Rs m3,12810,255 30.5%   
Total revenues Rs m135,281300,914 45.0%   
Gross profit Rs m66,29063,076 105.1%  
Depreciation Rs m5,20217,533 29.7%   
Interest Rs m44,0975,553 794.2%   
Profit before tax Rs m20,11950,246 40.0%   
Minority Interest Rs m3,1940-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-12,144 0.0%   
Tax Rs m8,6116,009 143.3%   
Profit after tax Rs m14,70132,093 45.8%  
Gross profit margin %50.221.7 231.1%  
Effective tax rate %42.812.0 357.9%   
Net profit margin %11.111.0 100.8%  
BALANCE SHEET DATA
Current assets Rs m122,742310,692 39.5%   
Current liabilities Rs m310,810173,396 179.2%   
Net working cap to sales %-142.347.2 -301.3%  
Current ratio x0.41.8 22.0%  
Inventory Days Days2399 23.3%  
Debtors Days Days39112 34.8%  
Net fixed assets Rs m116,904232,477 50.3%   
Share capital Rs m3692,399 15.4%   
"Free" reserves Rs m272,161411,691 66.1%   
Net worth Rs m272,530414,091 65.8%   
Long term debt Rs m270,19615,226 1,774.6%   
Total assets Rs m856,261646,938 132.4%  
Interest coverage x1.510.0 14.5%   
Debt to equity ratio x1.00 2,696.3%  
Sales to assets ratio x0.20.4 34.4%   
Return on assets %6.95.8 118.0%  
Return on equity %5.47.8 69.6%  
Return on capital %12.410.2 122.1%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m15,20066,025 23.0%   
Fx outflow Rs m4,88938,610 12.7%   
Net fx Rs m10,31227,415 37.6%   
CASH FLOW
From Operations Rs m-115,97521,965 -528.0%  
From Investments Rs m-8,265-6,813 121.3%  
From Financial Activity Rs m107,525-27,305 -393.8%  
Net Cashflow Rs m-16,650-8,442 197.2%  

Share Holding

Indian Promoters % 52.9 63.7 83.0%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 4.0 5.1 78.0%  
FIIs % 26.6 23.0 115.7%  
ADR/GDR % 0.0 0.0 -  
Free float % 16.5 8.3 198.8%  
Shareholders   93,274 133,026 70.1%  
Pledged promoter(s) holding % 0.0 0.5 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PIRAMAL ENTERPRISES With:   DR. REDDYS LAB  IPCA LABS  NATCO PHARMA  NEULAND LABS  PFIZER  

Compare PIRAMAL ENTERPRISES With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 110 Points Lower; Smallcap & Midcap Stocks Outperform(Closing)

Indian share markets witnessed volatile trading activity throughout the day today and ended marginally lower, ahead of Q2 GDP data.

Related Views on News

SUN PHARMA Announces Quarterly Results (2QFY21); Net Profit Up 66.9% (Quarterly Result Update)

Nov 6, 2020 | Updated on Nov 6, 2020

For the quarter ended September 2020, SUN PHARMA has posted a net profit of Rs 19 bn (up 66.9% YoY). Sales on the other hand came in at Rs 86 bn (up 5.3% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

PIRAMAL ENTERPRISES Announces Quarterly Results (1QFY21); Net Profit Up 22.1% (Quarterly Result Update)

Aug 25, 2020 | Updated on Aug 25, 2020

For the quarter ended June 2020, PIRAMAL ENTERPRISES has posted a net profit of Rs 5 bn (up 22.1% YoY). Sales on the other hand came in at Rs 29 bn (down 16.2% YoY). Read on for a complete analysis of PIRAMAL ENTERPRISES's quarterly results.

SUN PHARMA Announces Quarterly Results (4QFY20); Net Profit Down 31.6% (Quarterly Result Update)

May 28, 2020 | Updated on May 28, 2020

For the quarter ended March 2020, SUN PHARMA has posted a net profit of Rs 5 bn (down 31.6% YoY). Sales on the other hand came in at Rs 82 bn (up 14.3% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

SUN PHARMA Announces Quarterly Results (3QFY20); Net Profit Down 29.8% (Quarterly Result Update)

Feb 7, 2020 | Updated on Feb 7, 2020

For the quarter ended December 2019, SUN PHARMA has posted a net profit of Rs 10 bn (down 29.8% YoY). Sales on the other hand came in at Rs 82 bn (up 5.4% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

PIRAMAL ENTERPRISES Announces Quarterly Results (3QFY20); Net Profit Up 11.7% (Quarterly Result Update)

Feb 5, 2020 | Updated on Feb 5, 2020

For the quarter ended December 2019, PIRAMAL ENTERPRISES has posted a net profit of Rs 6 bn (up 11.7% YoY). Sales on the other hand came in at Rs 38 bn (up 9.1% YoY). Read on for a complete analysis of PIRAMAL ENTERPRISES's quarterly results.

More Views on News

Most Popular

Stocks that Could Shine More than Gold After Diwali(Profit Hunter)

Nov 17, 2020

If the markets become volatile over the next few months, do this.

Not Infosys or Wipro. India's Next Wealth Creators Could Be Drone Stocks(Profit Hunter)

Nov 25, 2020

India's drones directorate signals the next big defence tech multibaggers.

How the New Margins Will Impact You(Fast Profits Daily)

Nov 25, 2020

The new rules on margins will come into effect from 1st December. Are you ready?

How to Build the Best Trading System(Fast Profits Daily)

Nov 20, 2020

In this video, I'll show you how to make the best trading system.

An Eraser and Some Pencils(The Honest Truth)

Nov 17, 2020

Ajit Dayal on the road ahead for the world after covid.

More

Covid-19 Proof
Multibagger Stocks

Covid19 Proof Multibaggers
Get this special report, authored by Equitymaster's top analysts now!
We will never sell or rent your email id.
Please read our Terms

PIRAMAL ENTERPRISES SHARE PRICE


Nov 27, 2020 (Close)

TRACK PIRAMAL ENTERPRISES

  • Track your investment in PIRAMAL ENTERPRISES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON PIRAMAL ENTERPRISES

PIRAMAL ENTERPRISES 5-YR ANALYSIS

COMPARE PIRAMAL ENTERPRISES WITH

MARKET STATS